Medical Tidbits, Possible New Diabetes Treatment

Light it blue in support of Prostate Cancer Awareness month.
Light it blue in support of Prostate Cancer Awareness month.

Light it blue in support of Prostate Cancer Awareness.

Victoza® (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial

Stockholm, Sweden, 16 September 2015 Findings from a head-to-head trial comparing Victoza® (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 diabetes.Results from the LIRA-LIXI trial were announced today in an oral presentation at the 51st Annual Meeting of the European Association for the Study of Diabetes (EASD) in Stockholm, Sweden.  read more

Former Naurex Team Launches New Spin-Out Company, Aptinyx Preclinical NMDA Receptor Modulators and Discovery Platform Spun Out of Naurex upon Close of Acquisition by Allergan

EVANSTON, Ill., Sept. 16, 2015 /PRNewswire/ — Aptinyx Inc., a biopharmaceutical company advancing modulators of the N-methyl-D-aspartate (NMDA) receptor for the treatment of challenging disorders of the brain and nervous system, has launched with the discovery platform and preclinical pipeline spun out of Naurex upon the close of its acquisition by Allergan in August 2015. read more

Janssen: New pan-European survey reveals that only 14% of healthcare professionals feel sufficiently equipped to address prostate cancer patients’ quality of life issues

which details the findings from a large pan-European survey of 765 prostate cancer patients, 335 caregivers and 400 healthcare professionals, reveals that only 14 per cent of healthcare professionals feel that they have sufficient resources to address quality of life issues, such as fatigue, pain and intimacy problems.1  read more

InSite Vision and Sun Pharma Enter into Merger Agreement

ALAMEDA, Calif.–(EON: Enhanced Online News)–InSite Vision Inc. (OTCBB: INSV) today announced that InSite and a subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma) have entered into a merger agreement under which an indirect wholly owned subsidiary of Sun Pharma will acquire InSite in an all-cash transaction for $0.35 per share, or approximately $48 million in aggregate equity value, on a fully diluted basis. The transaction has been approved by the boards of directors of both InSite and the Sun Pharma subsidiary, and will be completed by means of a tender offer. read more

Cardinal Health Introduces Hospital Quality at Home™ Products

DUBLIN, Ohio, Sept. 15, 2015 /PRNewswire/ — Cardinal Health, which provides medical products and services to many of America’s most prestigious medical institutions, today announced the launch of the Hospital Quality at Home™ brand, a new line of hospital-quality products available over the counter to help loved ones and caregivers transition care from the hospital to home. The product line provides a full assortment of hospital-quality products for consumers categorized as Advanced Wound Care, First Aid, Personal Care, and Home Healthcare which help provide comfort and independence, while helping to promote healing. read more

J&J wants to be the healthiest worforce in the nation

On September 9th, the U.S. Surgeon General, Vice Admiral Vivek H. Murthy, issued a Call to Action to Promote Walking and Walkable Communities. This was only the 11th Call to Action in the 144-year span of the Surgeon General’s office, underscoring the severity of America’s level of inactivity. –  read more

Amgen And Xencor Announce Strategic Collaboration In Cancer Immunotherapy And Inflammation

THOUSAND OAKS, Calif. and MONROVIA, Calif., Sept. 16, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) and Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. The research collaboration brings together Amgen’s capabilities in target discovery and protein therapeutics with Xencor’s XmAb® bispecific technology platform. read more



Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.